Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Provectus BiopharmaceuticalsSTU:PXY 35 OCF Yield % is -9.93 as of Aug. 03, 2026. GuruFocus rates STU:PXY with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, Provectus Biopharmaceuticals ranks worse than 52.37% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Provectus Biopharmaceuticals OCF Yield % Related Terms
Provectus Biopharmaceuticals OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PXY vs PSTV, ALGS, ATNM: OCF Yield % Comparison
For the Biotechnology subindustry, Provectus Biopharmaceuticals's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Provectus Biopharmaceuticals OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Provectus Biopharmaceuticals's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Provectus Biopharmaceuticals (STU:PXY) has a OCF Yield % of -9.93 as of Aug. 03, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Provectus Biopharmaceuticals and its competitors. According to the industry distribution chart, Provectus Biopharmaceuticals ranks #739 out of 1411 companies in the Biotechnology industry, placing it in the top 52.4%.
Is Provectus Biopharmaceuticals' OCF Yield % too high?
Provectus Biopharmaceuticals' current OCF Yield % is -9.93. Based on the distribution chart, Provectus Biopharmaceuticals ranks #739 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Provectus Biopharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Provectus Biopharmaceuticals' OCF Yield % compare to PSTV and ALGS?
According to the Biotechnology industry distribution chart, Provectus Biopharmaceuticals ranks #739 out of 1411 companies for OCF Yield %. This places Provectus Biopharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Provectus Biopharmaceuticals and its competitors. Provectus Biopharmaceuticals's current OCF Yield % is -9.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provectus Biopharmaceuticals stock overvalued right now?
Provectus Biopharmaceuticals (STU:PXY) has a current OCF Yield % of -9.93. The current OCF Yield % is -9.93. Provectus Biopharmaceuticals' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Provectus Biopharmaceuticals (STU:PXY), the current OCF Yield % is -9.93 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.
35GF Score
Get the complete analysis for STU:PXY
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PXY has been successfully added to your 
